Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, includes centralized costs incurred by the Company.
Industry, Sector and Symbol:
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:CXRX
- CUSIP: N/A
- Web: www.concordiarx.com
- Market Cap: $65.9 million
- Outstanding Shares: 51,089,000
- 50 Day Moving Avg: $1.39
- 200 Day Moving Avg: $2.03
- 52 Week Range: $1.25 - $34.52
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 1.01
- P/E Growth: 0.00
- Annual Revenue: $748.18 million
- Price / Sales: 0.09
- Book Value: ($8.59) per share
- Price / Book: -0.15
- EBIDTA: $380.7 million
- Net Margins: -81.40%
- Return on Equity: 22.81%
- Return on Assets: 3.48%
- Debt-to-Equity Ratio: 10.65%
- Current Ratio: 1.02%
- Quick Ratio: 0.82%
- Average Volume: 521,834 shs.
- Beta: 0.12
- Short Ratio: 4.85
Frequently Asked Questions for Concordia International Corp (NASDAQ:CXRX)
What is Concordia International Corp's stock symbol?
Concordia International Corp trades on the NASDAQ under the ticker symbol "CXRX."
How were Concordia International Corp's earnings last quarter?
Concordia International Corp (NASDAQ:CXRX) posted its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of $0.52 by $0.89. The firm earned $160.56 million during the quarter, compared to analyst estimates of $168.09 million. Concordia International Corp had a negative net margin of 81.40% and a positive return on equity of 22.81%. The company's revenue was down 29.7% on a year-over-year basis. During the same period last year, the company earned ($0.09) EPS. View Concordia International Corp's Earnings History.
Where is Concordia International Corp's stock going? Where will Concordia International Corp's stock price be in 2017?
8 equities research analysts have issued 12-month target prices for Concordia International Corp's stock. Their predictions range from $0.50 to $14.00. On average, they anticipate Concordia International Corp's share price to reach $9.80 in the next year. View Analyst Ratings for Concordia International Corp.
Who are some of Concordia International Corp's key competitors?
Some companies that are related to Concordia International Corp include Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), Invuity (IVTY), 22nd Century Group (XXII), Trinity Biotech plc (TRIB), Cytosorbents Corp (CTSO), Vital Therapies (VTL), VIVUS (VVUS), ProQR Therapeutics NV (PRQR), CTI BioPharma Corp (CTIC), Adverum Biotechnologies (ADVM), Protalix Biotherapeutics (PLX), AcelRx Pharmaceuticals (ACRX), Arrowhead Pharmaceuticals (ARWR), Neovasc Inc (US) (NVCN), Cidara Therapeutics (CDTX), Cumberland Pharmaceuticals (CPIX) and Albireo Pharma (ALBO).
Who are Concordia International Corp's key executives?
Concordia International Corp's management team includes the folowing people:
- Jordan M. Kupinsky J.D., Chairman of the Board
- Wayne Kreppner, President, Chief Operating Officer
- Allan Oberman, Chief Executive Officer, Director
- David J. Price, Chief Financial Officer
- Graeme Duncan, President - Company's International Segment
- Arijit Mookerjee, Managing Director, Chief Financial Officer - Operations
- Adeel Ahmad, Chief Financial Officer of AMCo
- Francesco Tallarico, Chief Legal Officer and Secretary
- Patrick Vink M.D., Director
- Douglas N. Deeth, Independent Director
Who owns Concordia International Corp stock?
Concordia International Corp's stock is owned by many different of institutional and retail investors. Top institutional investors include Morgan Stanley (1.98%), Renaissance Technologies LLC (0.32%), Continental Advisors LLC (0.28%), Dimensional Fund Advisors LP (0.22%), Toronto Dominion Bank (0.16%) and FMR LLC (0.13%). View Institutional Ownership Trends for Concordia International Corp.
Who sold Concordia International Corp stock? Who is selling Concordia International Corp stock?
Who bought Concordia International Corp stock? Who is buying Concordia International Corp stock?
How do I buy Concordia International Corp stock?
Shares of Concordia International Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Concordia International Corp's stock price today?
MarketBeat Community Rating for Concordia International Corp (NASDAQ CXRX)MarketBeat's community ratings are surveys of what our community members think about Concordia International Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Concordia International Corp stock can currently be purchased for approximately $1.29.
Earnings History for Concordia International Corp (NASDAQ:CXRX)Earnings History by Quarter for Concordia International Corp (NASDAQ CXRX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/10/2017||3/31/2017||$0.52||($0.37)||$168.09 million||$160.56 million||View||N/A|
|3/15/2017||12/31/2016||$0.55||$0.13||$181.65 million||$170.40 million||View||N/A|
|11/7/2016||Q316||$1.03||($0.33)||$206.00 million||$185.50 million||View||Listen|
|8/12/2016||Q216||$1.38||$1.38||$229.76 million||$231.70 million||View||N/A|
|5/13/2016||Q116||$1.54||$1.35||$231.00 million||$228.50 million||View||N/A|
|3/23/2016||Q415||$1.32||$1.24||$166.60 million||$191.90 million||View||N/A|
|11/12/2015||Q315||$1.43||$1.46||$93.11 million||$94.90 million||View||N/A|
|8/13/2015||Q215||$1.02||$0.96||$78.60 million||$77.51 million||View||N/A|
Earnings Estimates for Concordia International Corp (NASDAQ:CXRX)
Current Year EPS Consensus Estimate: $1.26 EPS
Next Year EPS Consensus Estimate: $1.28 EPS
Dividend History by Quarter for Concordia International Corp (NASDAQ CXRX)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading History for Concordia International Corp (NASDAQ:CXRX)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Concordia International Corp (NASDAQ:CXRX)
Latest Headlines for Concordia International Corp (NASDAQ:CXRX)
Concordia International Corp (CXRX) Chart for Tuesday, May, 30, 2017